Long-Term Testosterone Treatment Leads to Sustained Weight Loss in Hypogonadal Men: Results from a Propensity-Matched Subgroup of a Controlled Registry Study

This case study concluded that weight loss is the initial recommended approach for treating secondary hypogonadism, as shown by improvements in testosterone levels and symptoms in an obese 37-year-old patient.

In this study, five-year testosterone replacement therapy improved fasting blood sugar, HbA1c, and triglyceride levels in Japanese hypogonadal men without significantly affecting prostate-specific antigen levels.

This study found that while a transscrotal testosterone patch increases serum testosterone levels in hypogonadal men with AIDS and weight loss, it does not improve weight, body cell mass, or quality of life.

In this study, female-to-male transsexuals treated with long-acting testosterone undecanoate experienced an increase in lean mass but no change in fat mass or bone mineral density over 24 months.

In this study, transgender adolescents treated with testosterone for a median of 12 months experienced effective virilization, including voice deepening and increased hair growth, but also showed decreased HDL cholesterol and BMD z-scores, and increased hematocrit, with no short-term safety issues reported.